1. Volume 377, Issue 9784, Pages 2181-2192 (June 2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo- controlled trial 
Prof Colin Baigent, FRCP, Martin J Landray, FRCP, Christina Reith, MRCP, Jonathan Emberson, PhD, David C Wheeler, FRCP, Charles Tomson, DM, Prof Christoph Wanner, MD, Vera Krane, MD, Prof Alan Cass, FRACP, Prof Jonathan Craig, PhD, Prof Bruce Neal, FRCP, Lixin Jiang, MD, Lai Seong Hooi, FRCP, Prof Adeera Levin, FRCPC, Prof Lawrence Agodoa, FACP, Prof Mike Gaziano, MD, Prof Bertram Kasiske, FACP, Prof Robert Walker, FRACP, Prof Ziad A Massy, MD, Prof Bo Feldt-Rasmussen, MD, Udom Krairittichai, MD, Vuddidhej Ophascharoensuk, MD, Prof Bengt Fellström, MD, Hallvard Holdaas, MD, Prof Vladimir Tesar, FASN, Prof Andrzej Wiecek, FRCP, Prof Diederick Grobbee, FESC, Prof Dick de Zeeuw, MD, Prof Carola Grönhagen-Riska, MD, Tanaji Dasgupta, MRCP, David Lewis, MRCP, William Herrington, MRCP, Marion Mafham, MD, William Majoni, FRACP, Karl Wallendszus, MSc, Prof Richard Grimm, MD, Prof Terje Pedersen, MD, Jonathan Tobert, PhD, Prof Jane Armitage, FRCP, Alex Baxter, BA, Christopher Bray, PhD, Yiping Chen, DPhil, Prof Zhengming Chen, DPhil, Michael Hill, DPhil, Carol Knott, MSc, Sarah Parish, DPhil, David Simpson, Prof Peter Sleight, MD, Alan Young, DPhil, Prof Rory Collins, FMedSci 
The Lancet 
Volume 377, Issue 9784, Pages (June 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events
Numbers remaining at risk of a first major atherosclerotic event at the beginning of each year are shown for both treatment groups.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

4. Figure 3 Major atherosclerotic events subdivided by type
MI=myocardial infarction. CHD=coronary heart disease.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

5. Figure 4 Major atherosclerotic events by baseline characteristics
χ2 tests on 1 degree of freedom are shown for heterogeneity between rate ratios within dichotomous categories and for trend within other categories. BP=blood pressure. MDRD=Modified Diet in Renal Disease formula.17 GFR=glomerular filtration rate.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

6. Figure 5 Cause-specific and overall mortality
CHD=coronary heart disease.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

7. Figure 6
Effects of LDL-lowering therapy on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials in other patients
Data from the Cholesterol Treatment Trialists' Collaboration.5 χ2 tests are shown for heterogeneity between rate ratios for each outcome in the four trials (4D,19 ALERT,21 AURORA,20 and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions